Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 2Breast Neoplasms 2Stomatitis 1Rectal Neoplasms 1Periodontitis 1Neoplasms, Plasma Cell 1Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Febrile Neutropenia 1EGFR-Mutant Lung Cancer 1Deglutition Disorders 1Communication Disorders 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma 1

Interventions

Lead 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × EGFR-Mutant Lung Cancer × Lead × Clear all
NCT01967095 2018-11-13

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
53 enrolled
Thoracic

EGFR-Mutant Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡